Global Myelofibrosis Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight

2022年06月17日00:00

Myelofibrosis Pipeline constitutes 45+ key companies continuously working towards developing 45+ Myelofibrosis treatment therapies, analyzes DelveInsight

Las Vegas, USA, June 16, 2022 (GLOBE NEWSWIRE) -- Global Myelofibrosis Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight

Myelofibrosis Pipeline constitutes 45+ key companies continuously working towards developing 45+ Myelofibrosis treatment therapies, analyzes DelveInsight

DelveInsight’s Myelofibrosis Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Myelofibrosis pipeline domain.

Some of the essential takeaways from the Myelofibrosis Pipeline report:

  • DelveInsight’s Myelofibrosis Pipeline analysis depicts a robust space with 45+ active players working to develop 45+ Myelofibrosis pipeline treatment therapies.
  • Some of the key Myelofibrosis companies proactively working to develop potential drug candidates to improve the Myelofibrosis treatment options include Pharmaxis, Keros Therapeutics, Bristol-Myers Squibb, Ascentage Pharma Group Inc., Sumitomo Pharma Oncology, Galecto Biotech AB, Actuate Therapeutics Inc, Karyopharm Therapeutics Inc, AbbVie, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Taiga Biotechnologies, Inc., Rigel Pharmaceuticals, Celgene, Novartis Pharmaceuticals, Sierra Oncology, Inc., Incyte Corporation, Imago BioSciences, Inc., Samus Therapeutics, Inc., Constellation Pharmaceuticals, Kartos Therapeutics, Inc., NS Pharma, Inc., Nippon Shinyaku Co., Ltd., Geron Corporation, Inc., Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Hoffmann-La Roche, Lynk Pharmaceuticals Co., Ltd, Chengdu Zenitar Biomedical Technology Co., Ltd, Prelude Therapeutics, Cellenkos, Jacobio Pharmaceuticals, Active Biotech, The Menarini Group, Cyclica Inc, GAT Therapeutics, Hinova pharmaceuticals, iOnctura, Telios Pharma, Inc. and many others.
  • Essential Myelofibrosis pipeline therapies such as PXS-5505, KER-050, BMS-986158, APG-1252, TP-3654, GB2064, 9-ING-41, Selinexor, TL-895, Mivebresib, Navitoclax, ABBV-744, Navitoclax, TQ05105, TBX-2400, Fostamatinib, ACE-536, Panobinostat, Momelotinib, Itacitinib, Parsaclisib, Bomedemstat, PU-H71, Pelabresib, KRT-232, NS-018, Imetelstat, TL-895, Jaktinib, Pomalidomide, MMB, RO7490677, INCB057643, LNK01002, INCB000928, LDE225, Flonoltinib, PRT543, CK0804, JAB-8263, Tasquinimod, and others are under development in different phases of clinical trials.
  • In June 2022, Cellenkos announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase Ib, open-label study of CK0804 as an add-on therapy to ruxolitinib in patients with myelofibrosis who experience a suboptimal response to ruxolitinib.
  • In June 2022, announced the US FDA granted Orphan Drug Designation for TP-3654, Sumitomo Pharma Oncology's proprietary investigational oral inhibitor of PIM kinases, for the treatment of myelofibrosis.
  • In June 2022, Imago Biosciences presented updated positive data from its ongoing global Phase II clinical study evaluating bomedemstat in patients with advanced myelofibrosis. Bomedemstat was generally safe and well-tolerated in patients with myelofibrosis. The most common non-hematologic adverse event (AE) related to bomedemstat was dysgeusia (altered taste), which occurred in 36% of patients, and dysgeusia led to discontinuation in 1 patient. There were 14 serious adverse events (SAEs) deemed related to bomedemstat per the Investigator.
  • In May 2022, Active Biotech announced that US FDA has granted tasquinimodOrphan Drug Designation for the treatment of myelofibrosis.
  • In June 2022, AbbVie announced new data from Cohort 3 of its Phase II REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naïve patients with myelofibrosis (MF), a rare and difficult to treat blood cancer. These data reinforced the importance of early intervention in myelofibrosis and the potential to achieve improved clinical outcomes.
  • In February 2022, Active Biotech entered into an exclusive license agreement with Oncode Institute in the Netherlands, for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in the treatment of myelofibrosis.
  • In April 2022, GlaxoSmithKline has announced the agreed $1.9bn acquisition of biopharmaceutical company Sierra Oncology, which specializes in treatments for rare forms of cancer. This news comes in the wake of Sierra Oncology’s positive top-line results from the MOMENTUM phase III trial earlier this year. This treatment represents a strong asset to complement GSK’s existing hematology portfolio.

Request a sample and discover more about the report offerings @ Myelofibrosis Emerging Therapies

The Myelofibrosis pipeline report lays down detailed profiles of the pipeline assets, a comparative analysis of clinical and non-clinical stage Myelofibrosis pipeline products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Myelofibrosis pipeline landscape.

Myelofibrosis Overview

Myelofibrosis is a rare disorder in which normal bone marrow tissue is gradually replaced with a fibrous scar-like material. It is classified as a type of chronic leukemia and belongs to a group of blood disorders called myeloproliferative diseases. Over time, this leads to progressive bone marrow failure. Under normal conditions, the bone marrow provides a fine network of fibers on which the stem cells can divide and grow. Specialized cells in the bone marrow known as fibroblasts make these fibers. Myelofibrosis can be of two types primary myelofibrosis and secondary myelofibrosis. Due to a shortage of red blood cells, myelofibrosis symptoms include extreme tiredness (fatigue) or shortness of breath, whereas the loss of white blood cells can lead to an increased number of infections, and a reduction of platelets can cause easy bleeding or bruising.

Find out more about the disease and recent cancer research developments @ Myelofibrosis Pipeline Assessment

Myelofibrosis Pipeline Drugs

DrugCompanyPhaseMoARoA
LNK01002Lynk Pharmaceuticals Phase I Protein kinase inhibitors Oral
PU-H-71Samus Therapeutics Phase I HSP90 heat-shock protein inhibitors Oral
TBX-2400Taiga Biotechnologies Phase I Cell replacements Intravenous
PXS-5505Pharmaxis|Parexel Phase I/II Protein-lysine 6-oxidase inhibitors Oral
BMS-986158Bristol-Myers Squibb Phase I/II Bromodomain and extraterminal domain protein inhibitors Oral
TP-3654Sumitomo Pharma Oncology, Inc. Phase I/II 1 Phosphatidylinositol 3 kinase inhibitors; Proto oncogene proteins c pim 1 inhibitors Oral
KER-050 Keros Therapeutics, Inc. Phase II Erythropoiesis stimulants; Transforming growth factor beta inhibitors Subcutaneous
GB2064Galecto Biotech AB Phase II LOXL2 protein inhibitors Oral
9-ING-41Actuate Therapeutics Inc. Phase II Glycogen synthase kinase 3 beta inhibitors Intravenous
SelinexorKaryopharm Therapeutics Inc Phase II Exportin-1 protein inhibitors Oral
NavitoclaxAbbVie Phase III Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors Oral
MomelotinibSierra Oncology Phase III ACVR1 protein inhibitors; Janus kinase 1 inhibitors; Janus kinase-2 inhibitors Oral

Learn more about the novel and emerging Myelofibrosis pipeline therapies @ Myelofibrosis Pipeline Analysis

Myelofibrosis Pipeline Therapeutics Assessment

The Myelofibrosis Pipeline report proffers an integral view of the Myelofibrosis emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action and Route of Administration.

Scope of the Myelofibrosis Pipeline Report

  • Coverage: Global
  • Therapeutic Assessment By Myelofibrosis Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Myelofibrosis Clinical Trial Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration, Inactive candidates
  • Therapeutics AssessmentBy Myelofibrosis Route of Administration: Oral, Parenteral, Intravitreal, Subretinal, Topical, Molecule Type
  • Therapeutics AssessmentBy Myelofibrosis Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
  • Therapeutics AssessmentBy Myelofibrosis Mechanism of Action: Bromodomain and extraterminal domain protein inhibitors, Protein replacements; Transforming growth factor beta1 modulators, ACVR1 protein inhibitors, Glycogen synthase kinase 3 beta inhibitors, Exportin-1 protein inhibitors, ACVR1 protein inhibitors; Janus kinase 1 inhibitors; Janus kinase-2 inhibitor, LOXL2 protein inhibitors, Erythropoiesis stimulants; Transforming growth factor beta inhibitors, Bromodomain and extraterminal domain protein inhibitors.
  • Key Myelofibrosis Companies: Pharmaxis, Keros Therapeutics, Bristol-Myers Squibb, Ascentage Pharma Group Inc., Sumitomo Pharma Oncology, Galecto Biotech AB, Actuate Therapeutics Inc, Karyopharm Therapeutics Inc, AbbVie, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Taiga Biotechnologies, Inc., Rigel Pharmaceuticals, Celgene, Novartis Pharmaceuticals, Sierra Oncology, Inc., Incyte Corporation, Imago BioSciences, Inc., Samus Therapeutics, Inc., Constellation Pharmaceuticals, Kartos Therapeutics, Inc., NS Pharma, Inc., Nippon Shinyaku Co., Ltd., Geron Corporation, Inc., Suzhou Zelgen Biopharmaceuticals Co., Ltd, Hoffmann-La Roche, Lynk Pharmaceuticals Co., Ltd, Chengdu Zenitar Biomedical Technology Co., Ltd, Prelude Therapeutics, Cellenkos, Jacobio Pharmaceuticals, Active Biotech, The Menarini Group, Cyclica Inc, GAT Therapeutics, Hinova pharmaceuticals, iOnctura, Telios Pharma, Inc., and many others.
  • Key Myelofibrosis Pipeline Therapies: PXS-5505, KER-050, BMS-986158, APG-1252, TP-3654, GB2064, 9-ING-41, Selinexor, TL-895, Mivebresib, Navitoclax, ABBV-744, Navitoclax, TQ05105, TBX-2400, Fostamatinib, ACE-536, Panobinostat, Momelotinib, Itacitinib, Parsaclisib, Bomedemstat, PU-H71, Pelabresib, KRT-232, NS-018, Imetelstat, TL-895, Jaktinib, Pomalidomide, MMB, RO7490677, INCB057643, LNK01002, INCB000928, LDE225, Flonoltinib, PRT543, CK0804, JAB-8263, Tasquinimod, and others

Dive deep into rich insights for emerging therapies and assessment, visit @ Myelofibrosis Pipeline and Emerging Therapies

Table of Contents

1 Introduction
2 Executive Summary
3 Myelofibrosis: Overview
4 Pipeline Therapeutics
5 Late Stage Products (Phase III)
5.1 Momelotinib: Sierra oncology
6 Mid Stage Products (Phase II)
6.1 Selinexor: Karyopharma therapeutics
7 Early Stage Products (Phase I)
7.1 LNK01002: Lynk Pharmaceuticals
8 Preclinical and Discovery Stage Products
8.1 HC-X027: Hinova pharmaceuticals
9 Inactive Products
10 Collaborations Assessment- Licensing / Partnering / Funding
11 Myelofibrosis - Unmet Needs
12 Myelofibrosis - Market Drivers and Barriers
13 Appendix
14 About DelveInsight

For further information on the current Myelofibrosis pipeline therapeutics, reach out @ Myelofibrosis Ongoing Clinical Trials

Related Reports

Acute Myeloid Leukemia Pipeline

DelveInsight’s, “Acute Myeloid Leukemia (AML) Pipeline Insight, 2022,” report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in Acute Myeloid Leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including BioSight, GlycoMimetics, Novartis, Takeda, Menarini Group, ImmunoGen, Kartos Therapeutics, Plexxikon, Shijiazhuang Yiling Pharmaceutical, JW Pharmaceutical, Hanmi Pharmaceutical, GEMoaB Monoclonals, and several others.

Acute Lymphocytic Leukemia Pipeline

DelveInsight’s, “Acute Lymphocytic Leukemia (ALL) Pipeline Insight, 2022,” report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in Acute Lymphocytic Leukemia (ALL) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including PersonGen BioTherapeutics, Novartis Pharmaceuticals, Jazz Pharmaceuticals, Takara Bio Inc, Cellectis S.A., AbbVie, Autolus Limited, Juventas Cell Therapy Ltd., Pinze Life technology Co. Ltd, Celgene, and many others.

Chronic Lymphocytic Leukemia Pipeline

DelveInsight’s, “Chronic Lymphocytic Leukemia (CLL) Pipeline Insight, 2022,” report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including Octapharm, Celgene, Loxo Oncology, Janssen Research & Development, TG Therapeutics, AFA Insurance, MorphoSys AG, Bristol Myers Squibb, IO Biotech, Astex Pharmaceuticals, Novartis, Oncternal Therapeutics, and various others.

Chronic Myelocytic Leukemia Pipeline

DelveInsight’s, “Chronic Myelocytic Leukemia (CML) Pipeline Insight, 2022,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Chronic Myelocytic Leukemia (CML) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products, key companies including Novarits Oncology, Servier, Eltrombopag, Immune-Onc Therapeutics, H3 Biomedicine, Chroma Therapeutics, Nerviano Medical Sciences, Astex Pharmaceuticals, Takeda Oncology, Argenx, Kura Oncology, Incyte Corporation, Genentech, Inc., and others.

T-cell Leukemia Pipeline

DelveInsight's "T-cell Leukemia Pipeline Insight, 2022" report outlays comprehensive insights of present clinical development scenario and growth prospects across the T-cell Leukemia market. A detailed picture of the T-cell Leukemia pipeline landscape is provided, which includes the disease overview and T-cell Leukemia treatment guidelines. The report offers a comprehensive analysis of 15+ key players and 15+ key therapies including names such as Daiichi Sankyo, Bioniz, Otsuka Pharmaceutical, Seagen, Takeda, HUYA Bioscience, iCell Gene Therapeutics, Gracell Biotechnology, Ascentage Pharma Group, Celgene Corporation, Shorla Pharma, AVM Biotechnology, Expression Therapeutics, and many others.

CAR-T Pipeline Insights

DelveInsight’s, “CAR-T Pipeline Insights, 2022,” report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in the CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including, AbbVie Inc, Adaptimmune Therapeutics PLC, Amgen, Inc, Celgene, DiaCarta, Inc, Endocyte, Inc, F1 Oncology, Inc, Fate Therapeutics Inc, Gilead, Humanigen, Inc, Immune Therapeutics, Inc, Intrexon, Corp, Juno Therapeutics, Inc, Kite Pharma, Inc, Lion TCR Pte Ltd, MaxCyte, Inc, Mesoblast, Ltd., and others.

Interested to know more about the recent oncology breakthroughs happenings? Take a look at the posts below

Other Trending Healthcare Reports

LAG-3-Next Generation Immunotherapy Market | Infliximab Biosimilars Insight | Infantile Spasm Market | Germany Healthcare Outlook | Gender dysphoria Market | Functional Dyspepsia Market | Chronic Spontaneous Urticaria Market | Chronic Myelocytic Leukemia (CML) Market | CAR T-Cell Therapy for Multiple Myeloma Market | Blepharitis Market | Bacterial Conjunctivitis Market | Angioimmunoblastic T-Cell Lymphoma AITL Market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News

CONTACT: Contact Us

Shruti Thakur

info@delveinsight.com

+1(919)321-6187

www.delveinsight.com

關注我們Facebook專頁
    相關新聞
      更多瀏覽